Invesco Pharmaceuticals ETF (NYSEARCA:PJP) Shares Sold by Capital Investment Advisory Services LLC

Capital Investment Advisory Services LLC reduced its holdings in Invesco Pharmaceuticals ETF (NYSEARCA:PJP) by 24.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,308 shares of the company’s stock after selling 1,763 shares during the quarter. Capital Investment Advisory Services LLC’s holdings in Invesco Pharmaceuticals ETF were worth $404,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Kraft Davis & Associates LLC acquired a new position in Invesco Pharmaceuticals ETF during the fourth quarter worth $277,000. Modera Wealth Management LLC acquired a new position in Invesco Pharmaceuticals ETF during the third quarter worth $538,000. UBS Group AG increased its position in Invesco Pharmaceuticals ETF by 132.2% during the third quarter. UBS Group AG now owns 92,123 shares of the company’s stock worth $6,667,000 after buying an additional 52,455 shares in the last quarter. Commonwealth Retirement Investments LLC purchased a new position in Invesco Pharmaceuticals ETF during the fourth quarter worth $1,557,000. Finally, International Assets Investment Management LLC purchased a new position in Invesco Pharmaceuticals ETF during the fourth quarter worth $4,633,000.

Invesco Pharmaceuticals ETF Stock Performance

Invesco Pharmaceuticals ETF stock opened at $76.40 on Wednesday. The stock has a fifty day moving average of $77.94 and a two-hundred day moving average of $74.94. The company has a market capitalization of $268.17 million, a price-to-earnings ratio of 20.52 and a beta of 0.64. Invesco Pharmaceuticals ETF has a fifty-two week low of $67.75 and a fifty-two week high of $80.65.

About Invesco Pharmaceuticals ETF

PowerShares Dynamic Pharmaceuticals Portfolio (the Fund) is a non-diversified fund. The Fund seeks investment results that correspond generally to the price and yield of the Dynamic Pharmaceuticals Intellidex Index (the Index). The Index evaluates companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.